Elebsiran

CAT: 0804-HY-147266ASize: 1 EachDry Ice: NoHazardous: No
CAT#:0804-HY-147266ASize:1 Each
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Elebsiran (VIR-2218) is a siRNA that targets and degrades hepatitis B virus (HBV) and hepatitis D virus (HDV) RNA transcripts. Elebsiran leads to a significant decrease in HBV surface antigen (HBsAg) and a reduction in viral load. Elebsiran binds to the sialic acid-depleted glycoprotein receptor (ASGPR) on the surface of liver cells through the GalNAc ligand, achieving liver-targeted delivery and demonstrating improved liver safety. Elebsiran can be used for the study of chronic HBV/HDV infections[1][2][3].
CAS Number
[2648009-64-5]
Product Name Alternative
VIR-2218
UNSPSC
12352208
Target
HBV; Small Interfering RNA (siRNA)
Type
Oligonucleotides
Related Pathways
Anti-infection; Epigenetics
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/elebsiran-1.html
Solubility
10 mM in H2O
Smiles
[Elebsiran]
Molecular Formula
C485H658N158F9O294P39S6
Molecular Weight
14976.67
References & Citations
[1]Zhou J, et al. Therapy with murinized tobevibart and elebsiran is efficacious in a liver-chimeric mouse model of HDV infection. JHEP Rep. 2025 Mar 22;7 (6) :101400.|[2]Gupta SV, et al. Clinical and Preclinical Single-Dose Pharmacokinetics of VIR-2218, an RNAi Therapeutic Targeting HBV Infection. Drugs R D. 2021 Dec;21 (4) :455-465. |[3]Ji Y, et al. The Impact of Hepatitis B Surface Antigen Reduction via Small Interfering RNA Treatment on Natural and Vaccine (BRII-179) -Induced Hepatitis B Virus-Specific Humoral and Cellular Immune Responses. Gastroenterology. 2025 Jul;169 (1) :136-149.
Shipping Conditions
Room temperature
Scientific Category
Oligonucleotides
Clinical Information
Phase 3

Alternative Products

CatalogName
MBS5816521Elebsiran
MBS5824133Elebsiran sodium

Popular Products